Our passion is transforming the data we collect into engaging insights.
We are a full service provider of healthcare and pharmaceutical market research solutions backed by our Leave No Stone Unturned Guarantee.
Engaging Insights
Recognized in the health and pharmaceutical market research industry for our visually intuitive and engaging story-based reports, we move the boardroom conversation from understanding to taking action.
Superior Sample
Fueled by our proprietary market research panel of healthcare professionals, our in-house field team consistently delivers more target respondents and larger sample sizes.
Industry Expertise
Since 2003, we have conducted market research in a variety of health-related areas amassing deep expertise and proprietary norms within the pharmaceutical and healthcare industry.
Supporting our research services is the MD Analytics Panel: Perspectives in Health.
Welcoming all healthcare professionals to join our panel.
Topical Polls and Industry Trends
Leaders in Oncology
In oncology, the pace is fast and the competition fierce. Leaders stand out not only for groundbreaking therapies but also for building trust, brand recognition, and robust patient support programs.
MD Analytics surveyed U.S. and Canadian oncologists to learn which companies are in the lead and why. The findings reveal that perceived leadership goes beyond science alone; it’s about a commitment to patient care that resonates with both clinicians and patients.
View our latest infographic and blog to see how top companies are positioning themselves to maintain momentum and secure their place at the front of the field.
Use of Real-World Evidence in Oncology
Real-world evidence (RWE) is no longer a secondary data source, it’s becoming a core input in oncology treatment decisions. In a new survey of Canadian and U.S. oncologists, MD Analytics explores how RWE is being used in clinical practice, the scenarios where it’s most valuable, and what challenges still exist in applying it effectively.
Our latest infographic reveals where oncologists see the greatest benefit from RWE, how it supports complex decision-making, and what pharmaceutical companies can do to improve access, data quality, and clinical relevance.
The Shifting Demographics of Oncology Patients
A recent survey of oncologists in North America reveals a rising trend: more patients are being diagnosed with solid tumor cancers at a younger age. Backed by recent epidemiological studies, this shift is particularly evident in breast and colorectal cancers.
This demographic change is expected to impact treatment strategies, patient management, and how pharmaceutical companies support and communicate with younger patients. Explore the infographic to learn more about the implications for oncology care.
Your answers,
our guarantee.